Howard University Telehealth Training Center
Providing consultation, education and mentoring to healthcare professionals

News

The Latest from the Health Resources and Services Administration (HRSA)

This information is reprinted from the HRSA HIV/AIDS Bulletin. For additional information on HAB and HRSA check out the HRSA HAB website.

HRSA HIV/AIDS Bureau Update: Special Bulletin

April 14, 2021

CDC and FDA Call for Pause on Administration of J&J Vaccine

HHS released a joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine yesterday. Based on six reported cases of a rare and severe type of blood clot, HHS recommends that vaccine providers pause on administering the Johnson & Johnson (J&J) COVID-19 vaccine.

CDC’s Advisory Committee on Immunization Practices (ACIP) is meeting today. Yesterday, CDC and FDA provided additional information and answered questions at a media briefing. A recording of that media call is now available.

People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System.


HRSA EHE Pacific Community Member Virtual Listening Session: April 15

This HRSA listening session, which takes place tomorrow, April 15, 1:30 – 3:00 pm ET, will focus on the barriers and facilitators to achieving the goals of the Ending the HIV Epidemic Initiative in the Pacific Region (Region 9). This region covers Arizona, California, Hawaii, Nevada and the Pacific Islands (American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands and Palau).

People with HIV, public health leaders, stakeholders from organizations currently implementing HIV prevention and care programs and other community-based organizations, and staff from Federally Qualified Health Centers in the Pacific Region (Region 9) are invited to participate.

Register for the listening session.


Help Improve HRSA's HIV/AIDS Bureau Website

HRSA’s HIV/AIDS Bureau (HAB) is currently undergoing a website redesign, and we would like to hear from you.  We have developed a brief (15-20 minute) survey to allow Ryan White HIV/AIDS Program recipients and stakeholders to provide valuable feedback about how we can better organize the website and improve the content available.  As part of the survey, you’ll be shown a list of phrases and will be asked to group them in any way that feels right to you. You’ll then be asked to name each group.

The survey is on-demand and unmoderated, so you will be able to take the survey independently and at any time that works for you. The survey will be open until Monday, May 3.

Participate in the HAB Website Survey.


HAB You Heard Webinar: April 27

Join the Health Resources and Services Administration’s (HRSA) HIV/AIDS Bureau (HAB) for the April HAB You Heard webinar, which takes place April 27, 2:00 – 3:00 pm ET. The HAB You Heard webinar series, a monthly update from HAB, is being hosted on Zoom. All attendees are asked to register to participate in the webinar.

The April HAB You Heard webinar will include a new COVID-19 Data Report update, highlight COVID-19 vaccination information, and feature two new Recipient Spotlight presentations. All Ryan White HIV/AIDS Program recipients, subrecipients, stakeholders, and federal staff are encouraged to participate in the webinar.

Register for the webinar


Updated HIV/AIDS Bureau Site Visit Guidance

Given the importance of HRSA’s Ryan White HIV/AIDS Program (RWHAP) recipients in the local, state, and national response efforts, as well as CDC guidance, HAB will postpone all on-site visits planned through September 28, 2020. This decision is made in consideration of the potential impact to RWHAP service providers’ operations during the COVID-19 pandemic, HAB staff and consultants, as well as the need for staff to be available for immediate mission critical assignments.

Site visits are an important part of the RWHAP monitoring and oversight process. Therefore, HAB will reschedule the postponed comprehensive and other site visits as soon as is practical.


Updated COVID-19 FAQs

We continually update our Ryan White HIV/AIDS Program COVID-19 Frequently Asked Questions (FAQs) webpage, including new and updated questions on:


COVID-19 Resources

Thank you again for the vital work you do in your communities to provide care and treatment to people with HIV.

HRSA HAB COVID-19 FAQ Webpage Update

HRSA HAB is continually updating the Ryan White HIV/AIDS Program (RWHAP) COVID-19 Frequently Asked Questions (FAQs) webpage. Recently added or updated questions include:

  • Purpose of COVID-19 funding for RWHAP recipients;
  • RWHAP recipients using COVID-19 funding for telehealth costs; and
  • FY 2021 RWHAP Part C Early Intervention Services Notice of Funding Opportunity Postponed.

Access the COVID-19 FAQ Webpage.


Archived Webinar: CARES Act Funding and Ryan White HIV/AID Program Recipients

On April 15, HRSA HAB hosted the second All Grant Recipient Webinar to provide important information on the CARES Act funding awards for Ryan White HIV/AIDS Program recipients.

Access the webinar.

Download the MP3 file of the call.

(Not U.S. Government websites)


Ryan White HIV/AIDS Program Services Report (RSR) Reporting Deadline: April 30

HRSA’s HIV/AIDS Bureau (HRSA HAB) RWHAP Services Report (RSR) reporting deadline is Thursday, April 30, 2020.  The RSR is open and recipients can submit as early as possible; however, data will be accepted through April 30, 2020. We will continue to monitor COVID-19 activities and assess the impact on RWHAP recipient and subrecipient activities.  As always, DART and Data Support are available to assist you with any technical assistance needs.

Access DART and Data Support.

(Not a U.S. government website)


Updated HRSA HIV/AIDS Bureau Site Visit Guidance

Given the importance of HRSA’s Ryan White HIV/AIDS Program (RWHAP) recipients in the local, state, and national response efforts, as well as CDC guidance, HAB will postpone all site visits planned through July 31, 2020. This decision is made in consideration of the potential impact to RWHAP service providers’ operations during the COVID-19 outbreak, HAB staff and consultants, as well as the need for staff to be available for immediate mission critical assignments.

Site visits are an important part of the RWHAP monitoring and oversight process. Therefore, HAB will reschedule the postponed comprehensive and other site visits as soon as is practical.


FY 2021 RWHAP Part C EIS NOFO Update - Funding Opportunity is Postponed

HRSA’s HIV/AIDS Bureau (HAB) has received numerous communications from current recipients expressing concern that they will be unable to submit applications for competition due to extreme interruptions and barriers to normal business operations. HRSA recognizes that the COVID-19 pandemic is having a profound impact on recipients’ staffing resources and their ability to conduct business functions and effectively address the emergency needs of clients.

In consideration of these ongoing issues, HRSA has determined that the FY 2021 RWHAP Part C EISEGA NOFO (HRSA-21-060, -061, and -062) will be postponed. HRSA plans to host a competition for the entire RWHAP Part C EISEGA program in FY 2022 when recipients’ business operations are anticipated to be stabilized and the appropriate staff and resources are available to develop quality applications for competition.


Training Slides: COVID-19 Update for People with HIV (Technical Assistance)

A set of three training slides on what providers treating people with HIV should know about COVID-19 is now available. Overall learning objectives include identifying risk factors for and strategies to reduce severe COVID-19 in people with HIV, recognizing the importance of antiretroviral treatment and potential drug-drug interactions, and considerations related to people with HIV and COVID-19. Sections include:

  • Epidemiology, Virology, Clinical Presentation, Diagnostics;
  • Antiretroviral Therapy, Medication Access, Drug-interactions; and
  • Routine HIV Primary Care, COVID-19 Risk Reduction, Management of Patients & Staff with COVID-19.

The slides were developed by the South Central AIDS Education and Training Center.

Access the slides.

(Not a U.S. Government website)


Other News 

Webinar on Access to Care for People with HIV During COVID-19: May 7

This webinar, which takes place May 7, 2:00 – 3:00 pm ET, will cover state, federal, and insurer-level policies expanding access to Medicaid, Medicare, and private insurance during the COVID-19 crisis. Discussion will include considerations for Ryan White HIV/AIDS Program Part B/ADAP recipients, including best practices to adapt policies and procedures to ensure uninterrupted access to care. It is presented by the National Alliance of State and Territorial AIDS Directors (NASTAD).

To participate.

(Not a U.S. Government website)


Updated 2020 ADAP Formulary Database

The National Alliance of State and Territorial AIDS Directors (NASTAD) released the updated 2020 National AIDS Drug Assistance Program (ADAP) Formulary Database. The database provides an online, searchable, publicly available resource detailing state-by-state ADAP coverage of medications both individually and by drug class including HIV antiretroviral treatments, “A1” Opportunistic Infections medications, treatments for hepatitis B and C, mental health and substance use disorder treatment medications, and various vaccines and laboratory tests. It includes ADAP formulary coverage for all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands as of December 31, 2019.

Access the database.

(Not a U.S. Government website)


CDC Report on Newly Reported Acute and Chronic Hepatitis C Cases

CDC released a Vital Signs report showing a growing number of hepatitis C cases among young adults. This shift has prompted the CDC to revise its hepatitis C testing recommendations to increase and expand hepatitis C testing and quickly link people with hepatitis C virus infection to treatment.

View the report.


Virtual International AIDS Conference: July 6-10

The 23rd International AIDS Conference will be held virtually July 6-10. There will be virtual sessions and community networking including exhibitions, workshops, the Global Village, and satellites and pre-conferences.

For more information.

(Not a U.S. Government website)